Results 1 to 10 of about 791,464 (334)

Cutaneous leishmaniasis mimicking cutaneous lymphoma. [PDF]

IDCases, 2019
Cutaneous leishmaniasis (CL) is caused by protozoa of Leishmania genus that are transmitted to humans through the bite of sand flies (Lutzomyia and Phlebotomus). The infection is classically manifested as multiple or single ulcers affecting cutaneous and/
Pires CAA, Pereira NG, Moreira AG, Sena JMC, Costa CCC, Bastos TDS, Rodrigues FDN, Faustino EP, da Silva JRC, Dos Santos MAL.   +9 more
europepmc   +4 more sources

Recent advances in cutaneous lymphoma-implications for current and future classifications. [PDF]

Virchows Arch, 2023
The Revised European-American Classification of mature lymphoid neoplasms published in 1994 and the 2001, 2008 and 2016 WHO classifications that followed, were the product of international collaboration and consensus amongst haematopathologists ...
Goodlad JR, Cerroni L, Swerdlow SH.
europepmc   +2 more sources

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.

Blood, 2022
The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large.
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J.   +34 more
europepmc   +2 more sources

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. [PDF]

Br J Dermatol, 2021
The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front‐line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (
Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Stratigos A, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ.   +66 more
europepmc   +2 more sources

Cutaneous Lymphoma Associated with JAK Inhibitors: A Pharmacovigilance Analysis of the FAERS Database and Literature Review. [PDF]

Acta Derm Venereol
The increasing use of JAK inhibitors in clinical practice is raising concerns regarding the potential risk of cutaneous lymphoma. This study aimed to conduct a comprehensive search for cases of cutaneous lymphoma associated with JAK inhibitors in the ...
Lu L, Feng J, He H, Peng Y, Zhang S, Yang L, Liu Y, Wang T.   +7 more
europepmc   +2 more sources

Care and treatment for primary cutaneous lymphoma-associated ulcers: Two case reports. [PDF]

SAGE Open Med Case Rep
Primary cutaneous lymphoma is a heterogeneous group of cutaneous lymphocytic primary tumors belonging to the extranodal category of non-Hodgkin lymphoma.
Wei M, Wei J, Li J, Li R, Liu J.
europepmc   +2 more sources

What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?

Cells, 2023
Extracorporeal photopheresis (ECP) is an FDA-approved immunotherapy for cutaneous T-cell lymphoma, which can provide a complete response in some patients. However, it is still being determined who will respond well, and predictive biomarkers are urgently
Oleg E. Akilov
doaj   +1 more source

Comparison of ultra-high versus conventional dose rate radiotherapy in a patient with cutaneous lymphoma.

Radiotherapy and Oncology, 2022
A patient with a cutaneous lymphoma was treated on the same day for 2 distinct tumors using a 15 Gy single electron dose given in a dose rate of 0.08 Gy/second versus 166 Gy/second.
O. Gaide, F. Herrera, W. J. Sozzi, Patrik Gonçalves Jorge, Rémy Kinj, C. Bailat, F. Duclos, F. Bochud, J. Germond, M. Gondré, Till Boelhen, L. Schiappacasse, M. Ozsahin, R. Moeckli, J. Bourhis   +14 more
semanticscholar   +1 more source

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma

Cells, 2022
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and
Amy Xiao, Oleg E. Akilov
doaj   +1 more source

Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification.

Presse medicale, 2022
Primary cutaneous lymphomas are a heterogeneous group of cutaneous T-cell lymphomas (CTCL) and cutaneous B-cell lymphomas (CBCL) that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. In the last decade the 2005 WHO-
R. Willemze
semanticscholar   +1 more source